Advertisement
Full length article| Volume 210, P22-28, March 2017

Download started.

Ok

Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use

Published:November 20, 2016DOI:https://doi.org/10.1016/j.ejogrb.2016.11.022
Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use
Previous ArticleLong-term outcomes for different vaginal cuff closure techniques in robotic-assisted laparoscopic hysterectomy: A randomized controlled trial
Next ArticleMethotrexate-treated ectopic pregnancy: beta human chorionic gonadotropin serum changes as a success predictor using a mathematical model validation

      Abstract

      Objective

      To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine contraceptive system (LNG-IUS 12) for up to 5 years of use.

      Study design

      In this Phase III study, 2885 nulliparous and parous women aged 18–35 years were randomized to LNG‐IUS 8 or LNG-IUS 12 for 3 years. After 3 years, women using LNG-IUS 12 could continue for up to 2 additional years (5 years total). The primary outcome was occurrence of pregnancy (Pearl Index). Secondary outcomes included safety, bleeding, dysmenorrhea, discontinuations, and user satisfaction.

      Results

      From August 2007 through May 2008, out of 2885 women who were enrolled, 1453 were randomized to LNG-IUS 12. Placement was attempted in 1452/1453 (full analysis set). Mean age at baseline was 27.1 years; 39.5% were nulliparous. The cumulative 5-year Pearl Index (PI) was 0.29; the 5-year cumulative failure rate was 1.4%. The 5-year PI for ectopic pregnancy was 0.18. Over 5 years, 55.3% of women reported study drug-related treatment-emergent adverse events (TEAEs). Crude incidences of pelvic inflammatory disease, uterine perforation, and complete/partial LNG-IUS 12 expulsion were 0.6%, 0.2%, and 3.7%, respectively. Women using LNG-IUS 12 generally experienced less frequent bleeding over time. The incidence of amenorrhea during the last 90-day reference interval (end of Year 5) was 22.6%. Overall, 870 (59.9%) and 550 (37.9%) women completed 3 and 5 years of treatment, respectively; 77.8% of women who entered the extension phase completed 5 years of use. Over 5 years, 22.6% discontinued due to TEAEs, including 13 women who discontinued due to pregnancy; 76 discontinued due to bleeding problems including amenorrhea; and 163 discontinued due to desire for pregnancy, 71.2% of whom conceived within 12 months.

      Conclusion

      In this study including parous and nulliparous women, LNG-IUS 12 was highly effective over 5 years of use and associated with a favorable safety profile. LNG‐IUS 12 offers women a low-dose contraceptive option for up to 5 years.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 121: Long-acting reversible contraception: implants and intrauterine devices.
        Obstet Gynecol. 2011; 118: 184-196
        View in Article

      2. National Institute for Health and Clinical Excellence Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception. 2013. Available from: http://www.nice.org.uk/guidance/cg30/resources/cg30-longacting-reversible-contraception-full-guideline3. [Last accessed 26 January 2016].

        View in Article

      3. World Health Organization Medical eligibility criteria for contraceptive use: fifth edition. 2015. Available from: http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/. [Last accessed 4 February 2016].

        View in Article
      4. Committee on Adolescence Contraception for adolescents.
        Pediatrics. 2014; 134: e1244-e1256
        View in Article

      5. Bayer HealthCare Pharmaceuticals Inc Jaydess® Summary of Product Characteristics. 2015. Available from: http://www.medicines.org.uk/emc/medicine/28672. [Last accessed 4 February 2016].

        View in Article

      6. Actavis Liletta® Prescribing Information. 2015. Available from: http://pi.actavis.com/data_stream.asp?product_group=1960&p=pi&language=E. [Last accessed 19 November 2015].

        View in Article

      7. Bayer HealthCare Pharmaceuticals Inc. Mirena® (levonorgestrel-releasing intrauterine system) Prescribing Information. 2015. Available from: http://www.berlex.com/html/products/pi/Mirena_PI.pdf. [Last accessed 16 February 2016].

        View in Article
        • Nelson A.L.
        • Apter D.
        • Hauck B.
        • et al.
        Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial.
        Obstet Gynecol. 2013; 122: 1205-1213
        View in Article

      9. Faculty of Sexual & Reproductive Healthcare New Product Review from the Clinical Effectiveness Unit Jaydess® Levonorgestrel Intrauterine System (LNG-IUS). 2014. Available from: http://www.fsrh.org/documents/cec-ceu-newproductreview-jaydess-apr-14/cec-ceu-newproductreview-jaydess-apr-14.pdf. [Last accessed 1 December 2016].

        View in Article

      10. Faculty of Sexual & Reproductive Healthcare New Product Review from the Clinical Effectiveness Unit: Levosert. 2015. Available from: https://www.fsrh.org/documents/cec-ceu-newproductreview-levosert-apr-2015/cec-ceu-newproductreview-levosert-apr-2015.pdf. [Last accessed 1 December 2016].

        View in Article

      11. European Medicines Agency, Guideline on Clinical Investigation of Steroid Contraceptives in Women. 2005. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003349.pdf. [Last accessed 12 February 2016].

        View in Article
        • Benda N.
        • Gerlinger C.
        • van der Meulen E.A.
        • Endrikat J.
        Sample size calculation for clinical studies on the efficacy of a new contraceptive method.
        Biom J. 2004; 46: 141-150
        View in Article
        • Gerlinger C.
        • Endrikat J.
        • van der Meulen E.A.
        • Dieben T.O.
        • Düsterberg B.
        Recommendation for confidence interval and sample size calculation for the Pearl Index.
        Eur J Contracept Reprod Health Care. 2003; 8: 87-92
        View in Article
        • Eisenberg D.
        • Schreiber C.
        • Turok D.K.
        • et al.
        Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system.
        Contraception. 2015; 92: 10-16
        View in Article

      15. Bayer HealthCare. Data on File. 2015.

        View in Article
        • Gemzell-Danielsson K.
        • Schellschmidt I.
        • Apter D.
        A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena.
        Fertil Steril. 2012; 97: 616-622
        View in Article
        • Andersson K.
        • Odlind V.
        • Rybo G.
        Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial.
        Contraception. 1994; 49: 56-72
        View in Article
        • Malhotra R.
        • Ostbye T.
        • Riley C.M.
        • Finkelstein E.A.
        Young adult weight trajectories through midlife by body mass category.
        Obesity (Silver Spring). 2013; 21: 1923-1934
        View in Article
        • Andersson K.
        • Batar I.
        • Rybo G.
        Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T.
        Contraception. 1992; 46: 575-584
        View in Article
        • Sivin I.
        • Stern J.
        • Diaz S.
        • et al.
        Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
        Am J Obstet Gynecol. 1992; 166: 1208-1213
        View in Article
        • Mansour D.
        • Gemzell-Danielsson K.
        • Inki P.
        • Jensen J.T.
        Fertility after discontinuation of contraception: a comprehensive review of the literature.
        Contraception. 2011; 84: 465-477
        View in Article

      Article info

      Publication history

      Published online: November 20, 2016
      Accepted: November 19, 2016
      Received in revised form: November 14, 2016
      Received: September 16, 2016

      Footnotes

      ☆Clinical Trial Registration: ClinicalTrials.gov NCT00528112

      Identification

      DOI: https://doi.org/10.1016/j.ejogrb.2016.11.022

      Copyright

      © 2016 Elsevier Ireland Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX